4521 KAKEN PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4521

TSE Prime

KAKEN PHARMACEUTICAL CO.,LTD.

4,257

JPY

+20

(+0.47%)

Dec 23, 3:30 pm JST

27.18

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	74,979	17,788	18,222	13,405	347.4	150	May 7, 2021	J-GAAP
Mar, 2022	76,034	17,064	17,542	9,549	251.4	150	May 11, 2022	J-GAAP
Mar, 2023	72,984	7,998	8,727	5,440	144.8	150	May 10, 2023	J-GAAP
Mar, 2024	72,044	9,513	9,951	8,025	212.7	150	May 14, 2024	J-GAAP
Mar, 2025 Guidance	88,500	20,800	21,200	14,200	374.9	190	Aug 7, 2024	J-GAAP
YoY	+22.8%	+118.6%	+113.0%	+76.9%	+76.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 9, 2019	92,900	22,300	22,700	16,100	150	J-GAAP
	Mar 27, 2020	89,000	26,000	26,400	18,600	150	J-GAAP
Results	May 22, 2020	89,232	26,512	26,946	19,370	150	J-GAAP
Mar, 2021	May 22, 2020	Available in future release
	Oct 27, 2020
Results	May 7, 2021
Mar, 2022	May 7, 2021
	Mar 29, 2022
Results	May 11, 2022
Mar, 2023	May 11, 2022
	Feb 3, 2023
Results	May 10, 2023
Mar, 2024	May 10, 2023
Results	May 14, 2024
Mar, 2025	May 14, 2024	75,100	7,400	7,800	5,600	150	J-GAAP
	Aug 7, 2024	88,500	20,800	21,200	14,200	190	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	71,801	+7.4	Available in future release
Mar, 2001	70,305	-2.1
Mar, 2002	73,272	+4.2
Mar, 2003	74,002	+1.0
Mar, 2004	72,706	-1.8
Mar, 2005	74,922	+3.0
Mar, 2006	75,540	+0.8
Mar, 2007	76,415	+1.2
Mar, 2008	79,934	+4.6
Mar, 2009	82,930	+3.7
Mar, 2010	85,022	+2.5
Mar, 2011	86,428	+1.7
Mar, 2012	87,997	+1.8
Mar, 2013	87,054	-1.1
Mar, 2014	88,946	+2.2
Mar, 2015	93,889	+5.6
Mar, 2016	109,730	+16.9
Mar, 2017	101,479	-7.5
Mar, 2018	98,430	-3.0
Mar, 2019	94,165	-4.3
Mar, 2020	89,232	-5.2
Mar, 2021	74,979	-16.0
Mar, 2022	76,034	+1.4
Mar, 2023	72,984	-4.0
Mar, 2024	72,044	-1.3
Mar, 2025 Guidance	88,500	+22.8	20,800	+118.6	21,200	+113.0	374.9	+76.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	72,984	7,998	11.0	3.97	3.28	0.44	144.8
Mar, 2024	72,044	9,513	13.2	5.73	4.75	0.43	212.7
Mar, 2025 Guidance	88,500	20,800	23.5	9.20	7.59	0.47	374.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	109,730	35,146	35,365	22,017	536.7
Fiscal Year	Mar, 2016	Mar, 2016	Mar, 2016	Mar, 2017	Mar, 2017

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	38,446	8,028	8,252	2,828	74.5	75	May 11, 2022	J-GAAP
Oct - Mar, 2022	36,165	-211	172	-524	-14.0	75	May 10, 2023	J-GAAP
Oct - Mar, 2023	35,873	4,001	4,229	3,957	104.9	75	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	37,128	1,221	1,377	-86	-2.3	75	Nov 8, 2024	J-GAAP
YoY	+3.5%	-69.5%	-67.4%	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	17,064	5,448	13,336	-7,888	-8,129	74,625	45.18	J-GAAP
Mar, 2023	7,998	6,626	9,253	-2,627	-6,990	74,260	44.65	J-GAAP
Mar, 2024	9,513	-3,277	2,577	-5,854	-5,658	65,325	38.06	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	36,819	8,209	8,555	5,964	158.3	98.0	Nov 8, 2022	J-GAAP
Apr - Sep, 2023	36,171	5,512	5,722	4,068	108.2	57.5	Nov 8, 2023	J-GAAP
Apr - Sep, 2024	51,372	19,579	19,823	14,286	377.2	93.5	Nov 8, 2024	J-GAAP
YoY	+42.0%	+255.2%	+246.4%	+251.2%	+248.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	18,754	4,185	4,421	3,185	84.7	22.3	Feb 3, 2023	J-GAAP
Jan - Mar, 2023	17,411	-4,396	-4,249	-3,709	-98.7	-25.2	May 10, 2023	J-GAAP
Apr - Jun, 2023	18,150	3,293	3,488	2,510	67.0	18.1	Aug 4, 2023	J-GAAP
Jul - Sep, 2023	18,021	2,219	2,234	1,558	41.4	12.3	Nov 8, 2023	J-GAAP
Oct - Dec, 2023	18,514	3,361	3,582	2,607	69.2	18.2	Feb 6, 2024	J-GAAP
Jan - Mar, 2024	17,359	640	647	1,350	35.8	3.7	May 14, 2024	J-GAAP
Apr - Jun, 2024	18,254	2,750	3,011	1,754	46.3	15.1	Aug 7, 2024	J-GAAP
Jul - Sep, 2024	33,118	16,829	16,812	12,532	330.9	50.8	Nov 8, 2024	J-GAAP
YoY	+83.8%	+658.4%	+652.6%	+704.4%	+698.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	25,008	-0.2	Available in future release
Jan - Mar, 2020	19,054	-11.7
Apr - Jun, 2020	18,070	-19.1
Jul - Sep, 2020	18,719	-18.0
Oct - Dec, 2020	20,293	-18.9
Jan - Mar, 2021	17,897	-6.1
Apr - Jun, 2021	18,453	+2.1
Jul - Sep, 2021	19,135	+2.2
Oct - Dec, 2021	20,120	-0.9
Jan - Mar, 2022	18,326	+2.4
Apr - Jun, 2022	18,197	-1.4
Jul - Sep, 2022	18,622	-2.7
Oct - Dec, 2022	18,754	-6.8
Jan - Mar, 2023	17,411	-5.0
Apr - Jun, 2023	18,150	-0.3
Jul - Sep, 2023	18,021	-3.2
Oct - Dec, 2023	18,514	-1.3
Jan - Mar, 2024	17,359	-0.3
Apr - Jun, 2024	18,254	+0.6
Jul - Sep, 2024	33,118	+83.8	16,829	+658.4	16,812	+652.6	330.9	+699.3

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	33,118	16,829	16,812	12,532	330.9
Fiscal Year	Sep, 2024	Sep, 2024	Sep, 2024	Sep, 2024	Sep, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	3,642.34	83.4	165,181	137,747	126,347	0.03	May 11, 2022	J-GAAP
Mar, 2023	3,636.17	81.9	166,328	136,258	126,135	0.03	May 10, 2023	J-GAAP
Mar, 2024	3,796.05	83.8	171,623	143,755	128,506	0.03	May 14, 2024	J-GAAP
Apr - Sep, 2024	ー	82.5	187,123	154,405	139,949	0.02	Nov 8, 2024	J-GAAP

KAKEN PHARMACEUTICAL CO.,LTD.(4521) Financial Results